Braftovi (Encorafenib) for Lung Cancer

Overview
Braftovi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It’s indicated to be used in combination with Mektovi (Binimetinib). Braftovi is also referred to by its drug name, Encorafenib.

Braftovi is a member of the class of drugs called kinase inhibitors. Braftovi is believed to work by blocking the action of a gene that makes a protein some lung cancer cells need to divide and grow.

How do I take it?
Prescribing information states that Braftovi is taken orally as a capsule once daily, with or without food.

Braftovi should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Braftovi lists common side effects including fatigue, nausea, diarrhea, muscle and joint pain, vomiting, abdominal pain, vision problems, constipation, trouble breathing, rash, and cough.

Rare but serious side effects listed for Braftovi include new cancers, heart problems, liver problems, severe bleeding, eye inflammation, and fetal harm.

For more details about this treatment, visit:

Label: Braftovi — Encorafenib Capsule — DailyMed

Encorafenib — MedlinePlus